Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-diabetic Chronic Kidney Disease Atherosclerosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

omentin-1 carotid atherosclerosis kidney disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case Group

Patients with chronic kidney disease of stage 3-4.

No interventions assigned to this group

Control group

30 healthy subject

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria

* Chronic kidney disease of stage 5
* The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
* Severe heart failure
* Stage 2 hypertension
* Diabetes mellitus
* Corticosteroid therapy
* Severe hepatic disease
* Smoking
* Inflammatory disease
* Acute infectious disease
* Malignancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Erkan SENGUL, MD

Role: PRINCIPAL_INVESTIGATOR

Kocaeli Derince Education and Training Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital

İzmit, Kocaeli, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rabia TERZI, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012/02

Identifier Type: -

Identifier Source: org_study_id